Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emtricitabine/rilpivirine/tenofovir disoproxil fumarate - Gilead Sciences/Janssen R&D Ireland

Drug Profile

Emtricitabine/rilpivirine/tenofovir disoproxil fumarate - Gilead Sciences/Janssen R&D Ireland

Alternative Names: Complera; Edurant/Truvada; Emtricitabine/tenofovir disoproxil fumarate/rilpivirine; Emtricitabine/tenofovir disoproxil fumarate/TMC 278; Eviplera; Rilpivirine/emtricitabine/tenofovir disoproxil fumarate; Rilpivirine/Truvada; TDF/FTC/RPV; Tenofovir disoproxil fumarate/rilpivirine/emtricitabine; Truvada/Edurant™; Truvada/TMC278

Latest Information Update: 28 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gilead Sciences; Tibotec Pharmaceuticals
  • Developer Gilead Sciences; Janssen Pharmaceutical KK; Janssen R&D Ireland
  • Class Antiretrovirals; Deoxyribonucleosides; Nitriles; Nucleotides; Phosphonic acids; Purines; Pyrimidine nucleosides; Pyrimidines
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 07 Mar 2018 Gilead Sciences completes a phase III SWEAR trial for HIV-1 infections (Treatment naive) in Italy (PO) (NCT02042001)
  • 12 Feb 2018 Emtricitabine/rilpivirine/tenofovir disoproxil fumarate is still in phase III SALIF trials in HIV-1 infections (second-line therapy) in Cameroon, Ghana, Kenya, Senegal, South Africa, Thailand and Uganda (NCT01709084)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top